RATE protocol

chemotherapy protocol consisting of above 3 cpds & epipodophyllotoxin

Networked: 9 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - RATE protocol: 9
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - RATE protocol: 9
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - RATE protocol: 9
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidine Nucleosides: 50
      - Cytidine: 535
        Cytarabine: 6662
        RATE protocol: 9
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Thioguanine: 835
        RATE protocol: 9
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Pyrimidine Nucleosides: 50
    - Cytidine: 535
      - Cytarabine: 6662
        RATE protocol: 9
  - Arabinonucleosides: 1
    - Cytarabine: 6662
      - RATE protocol: 9
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Tetrahydronaphthalenes: 1
        Podophyllotoxin: 562
        RATE protocol: 9
        Naphthacenes
        Anthracyclines: 9423
        Daunorubicin: 2641
        RATE protocol: 9
      - Benzene Derivatives: 17
        Benzyl Compounds: 2
        Lignans: 1113
        Podophyllotoxin: 562
        RATE protocol: 9
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - Podophyllotoxin: 562
        RATE protocol: 9
  - Naphthacenes
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        RATE protocol: 9
Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        RATE protocol: 9

Experts

1.	Adelson, P David: 1 article (03/2022)
2.	Bobinski, Matthew: 1 article (03/2022)
3.	Casper, T Charles: 1 article (03/2022)
4.	Dean, J Michael: 1 article (03/2022)
5.	Ghetti, Simona: 1 article (03/2022)
6.	Hewes, Hilary A: 1 article (03/2022)
7.	Holmes, James F: 1 article (03/2022)
8.	Kuppermann, Nathan: 1 article (03/2022)
9.	Linakis, Seth W: 1 article (03/2022)
10.	Myers, Sage R: 1 article (03/2022)

Related Diseases

1.	Wounds and Injuries (Trauma) 03/10/2022 - "Based on enrollment rate, protocol adherence, and measurement of the primary outcome in this pilot trial, we confirmed the feasibility of conducting a large-scale, randomized trial evaluating the efficacy of TXA in severely injured children with hemorrhagic brain and/or torso injuries using EFIC."
2.	Pain (Aches) 01/01/2015 - "Primary outcomes were study feasibility (consent rate, protocol completion rate) and pain scores on study days 5 to 19. "
3.	Neoplasms (Cancer) 07/01/1999 - "The ability of L-NNA to correspondingly improve tumor response and severely limit skin vascular perfusion following high fluence rate PDT, while providing no benefit for the low fluence rate protocol, suggests that vascular changes in the tumor surrounding normal tissue contribute to the enhanced tumor curability with adjuvant L-NNA treatment." 03/01/1994 - "The ratio of nucleotide triphosphates to inorganic phosphate falls to 0.21 +/- 0.02 of initial values 5 h after tumors are treated with the lower fluence rate protocol, and falls to 0.40 +/- 0.06 in tumors treated with the higher fluence rate."
4.	Cardiomyopathies (Cardiomyopathy) 11/15/1997 - "Ten patients with stable CHF secondary to ischemic cardiomyopathy (ejection fraction 34 +/- 6%) (mean age 47 +/- 10 years) and 8 healthy matched control subjects underwent an upright incremental cycle ergometer exercise test with gas exchange analysis and a 6-minute constant work rate protocol at 60% of peak oxygen consumption (VO2). "
5.	Heart Failure 07/01/1990 - "Even with a low incremental work rate protocol, compared with sedentary normal subjects or patients without heart failure, patients with heart failure demonstrate impaired oxygen uptake. "

Related Drugs and Biologics

1.	Phosphates (Orthophosphate)
2.	Oxygen (Dioxygen)
3.	Nucleotides
4.	1-phenyl-3,3-dimethyltriazene (PDT)